Close

LOGIN

Remember me
Not a member?
or
Connect using:
Why BS?

We encourage visitors to register on Business Standard. Registering on the site is absolutely Free and offers you the following benefits.

Free Daily E-newsletter

Breaking News Alerts in your Inbox

Post Comments and Share your Feedback

Your Personal Business Standard Page

Free Portfolio of Stocks, Equity and Commodities Derivatives

Access Premium Services

Receive Selective Offers from our Third Party Premium Advertisers

Get Invited to Business Standard Events

Close

FORGOT PASSWORD?

Not a member?

Ranbaxy raises Rs 500 cr by issuing 5,000 NCDs

The debentures have been rated AA+ by CARE and are proposed to be listed on National Stock Exchange of India

Related News

Ranbaxy Laboratories today said it has raised Rs 500 crore via issue of non-convertible debentures to be utilised for general corporate purposes.

"The company on November 23, 2012 has issued 5,000 secured 9.20% redeemable Non-Convertible Debentures of face value of Rs 10,00,000 each, for cash at par, aggregating Rs 500 crore, on a private placement basis, for general corporate purposes," Ranbaxy Laboratories said in a filing to the BSE.

These debentures have been rated AA+ by CARE and are proposed to be listed on National Stock Exchange of India (NSE), it added.

Earlier in the day, the company had announced that it is recalling its generic version of cholesterol- lowering drug Lipitor from the US market, leading to temporary disruption in the supply.

The shares of the company declined by 3.27% from its previous closing price to end the day on the BSE at Rs 495.95 per scrip.

Read More

Telenor's 2008 licence fee may not be adjusted in new payment

Telenor may not be able to avail of the benefit of adjusting Rs 1,658 crore licence fee it paid in 2008 for permits of its Indian venture Uninor in ...

Back to Top

Quick Links

Back to Top